Mizoribine has been investigated for the treatment of Rheumatoid Arthritis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Mizoribine. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Mizoribine. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mizoribine. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mizoribine. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mizoribine. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mizoribine. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Mizoribine. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mizoribine. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mizoribine. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mizoribine. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Mizoribine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mizoribine. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mizoribine. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Mizoribine. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mizoribine. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mizoribine. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Mizoribine. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Mizoribine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Mizoribine. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mizoribine. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Mizoribine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mizoribine. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Mizoribine. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Mizoribine. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mizoribine. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mizoribine. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mizoribine. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mizoribine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Mizoribine. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Mizoribine. |
| Cladribine | Mizoribine may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Mizoribine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Mizoribine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Mizoribine. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mizoribine. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mizoribine. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Mizoribine. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mizoribine. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Mizoribine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Mizoribine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Mizoribine. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Mizoribine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Mizoribine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mizoribine. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mizoribine. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Mizoribine. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Mizoribine. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mizoribine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Mizoribine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Mizoribine. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Mizoribine. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Mizoribine. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Mizoribine. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Mizoribine. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Mizoribine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Mizoribine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Mizoribine. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mizoribine. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mizoribine. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Mizoribine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mizoribine. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mizoribine. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Mizoribine. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Mizoribine. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Mizoribine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Mizoribine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mizoribine. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mizoribine. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Mizoribine. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Mizoribine. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Mizoribine. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Mizoribine. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Mizoribine. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Mizoribine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mizoribine. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mizoribine. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mizoribine. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Mizoribine. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Mizoribine. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Mizoribine. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mizoribine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mizoribine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Mizoribine. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Mizoribine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Mizoribine. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Mizoribine. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Mizoribine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Mizoribine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Mizoribine. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mizoribine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mizoribine. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Mizoribine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Mizoribine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Mizoribine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Mizoribine. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Mizoribine. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mizoribine. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Mizoribine. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Mizoribine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Mizoribine. |